http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101300546-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-303 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2005-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101300546-B1 |
| titleOfInvention | Adjuvant Therapy with Anti-Glypican 3 Antibody |
| abstract | The present invention provides an anticancer agent containing an anti-Glypican 3 antibody, which is administered after cancer treatment. Preferably, the cancer treatment is after the treatment of liver cancer, in particular the liver cancer treatment is resection of liver cancer cells. Preferably, the anticancer agent of the present invention is used when the excised liver cancer cell glypican 3 is expressed. Also preferably, the anti-glycancan 3 antibody is a monoclonal antibody. The anticancer agent of the present invention is useful for the prevention or relapse prevention of cancer.n n n n Anti-Glypican 3 Antibody, Liver Cancer Treatment, Anticancer Drug |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102366820-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20160114088-A |
| priorityDate | 2004-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1272.